These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6849295)

  • 1. A study of optimal reaction conditions for an assay of the human alternative complement pathway.
    Joiner KA; Hawiger A; Gelfand JA
    Am J Clin Pathol; 1983 Jan; 79(1):65-72. PubMed ID: 6849295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the optimal reaction conditions for assay of the mouse alternative complement pathway.
    Van Dijk H; Rademaker PM; Klerx JP; Willers JM
    J Immunol Methods; 1985 Dec; 85(2):233-43. PubMed ID: 4078314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual complement-mediated hemolytic kinetics at low ionic strength.
    Chang NS; Boackle RJ
    Mol Immunol; 1985 Oct; 22(10):1217-24. PubMed ID: 4079941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid.
    Des Prez RM; Bryan CS; Hawiger J; Colley DG
    Infect Immun; 1975 Jun; 11(6):1235-43. PubMed ID: 806523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosaminoglycans enhance complement hemolytic efficiency: theoretical considerations for GAG-complement-saliva interactions.
    Chang NS; Boackle RJ
    Mol Immunol; 1986 Aug; 23(8):887-93. PubMed ID: 3796630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
    Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
    J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equine alternative pathway activation by unsensitized rabbit red blood cells.
    Leid RW; Coley SC; Blanchard DP; Perryman LE
    Vet Immunol Immunopathol; 1985 May; 9(1):71-85. PubMed ID: 4024451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feline (cat) hemolytic complement optimal testing conditions.
    Barta O; Oyekan PP
    Am J Vet Res; 1981 Mar; 42(3):378-81. PubMed ID: 6791533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of optimal in vitro conditions for caprine alternative complement pathway assay.
    Venugopal G; Ram GC; Bansal MP
    Vet Immunol Immunopathol; 1992 May; 32(3-4):359-64. PubMed ID: 1632071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway.
    Boackle RJ; Caughman GB; Vesely J; Medgyesi G; Fudenberg HH
    Mol Immunol; 1983 Nov; 20(11):1157-64. PubMed ID: 6228720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces.
    Kirschfink M; Kovacs B; Mottaghy K
    Circ Shock; 1993 Jul; 40(3):221-6. PubMed ID: 8348684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The classical and alternate pathways of complement in oral contraceptive users.
    Delâge JM; Lehner-Netsch G; Brisson J
    Contraception; 1987 Dec; 36(6):627-32. PubMed ID: 3446439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor.
    Czop JK; Austen KF
    J Immunol; 1985 Nov; 135(5):3388-93. PubMed ID: 4045195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemolytic assay for goat (caprine) and swine (porcine) complement.
    Oyekan PP; Barta O
    Vet Immunol Immunopathol; 1980 Dec; 1(4):317-28. PubMed ID: 15615050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential activation and depletion of the alternative complement pathway by burn injury.
    Gelfand JA; Donelan M; Burke JF
    Ann Surg; 1983 Jul; 198(1):58-62. PubMed ID: 6859992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement.
    Inada K
    Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):7-10. PubMed ID: 6778918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on activation and levels of haemolytic complement of buffalo (Bubalus bubalis). II. Alternate complement pathway activity in serum.
    Arya A; Goel MC
    Vet Immunol Immunopathol; 1992 Jan; 30(4):411-8. PubMed ID: 1546445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural hemolytic and bactericidal activities of sea bream Sparus aurata serum are effected by the alternative complement pathway.
    Sunyer JO; Tort L
    Vet Immunol Immunopathol; 1995 Apr; 45(3-4):333-45. PubMed ID: 7676614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Modification of proteolytic complement cascade after treatment with exogenous heparin].
    Galebskaia LV; Solovtsova IL; Riumina EV
    Vopr Med Khim; 2001; 47(1):91-7. PubMed ID: 11386002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.